The definitive treatment of a pancreatic tumour secreting vasoactive intestinal polypeptide is surgical removal ofthe tumour, but when curative resection is not possible symptomatic treatment ofthe endocrine hyperfunction is important. Streptozotocin, although effective for palliation, can involve unpleasant side effects. We report the long term use ofsubcutaneous somatostatin analogue SMS 201-995 in an elderly man presenting with severe watery diarrhoea and anaemia due to a pancreatic vipoma. Good symptomatic inprovement has been achieved with no side effects over a period of 24 months. We suggest there is a use for subcutaneous SMS 201-995 in elderly patients with inoperable pancreatic gut hormone producing tumours with metastases and in those where surgery would carry a high operative risk.
Introduction
The clinical picture of a pancreatic tumour secreting vasoactive intestinal peptide (vipoma) is dominated by diarrhoea, and associated with hypokalaemia, hypochlorhydria, and alkalosis.' An excess of vasoactive intestinal peptide (VIP) stimulates water secretion in the intestine and pancreas leading to a secretory diarrhoea which may be life threatening. The definitive treatment for a vipoma is surgical removal, but presentation may occur after the tumour has metastasized or when major surgery is contraindicated by the patient's general condition. Symptomatic treatment can be achieved with streptozotocin but this may have unpleasant side effects. Figure 1) ; period D 0600 h and 1800 h, period E 0900 h and 2100 h -this second period was suited to his meal times.
Subcutaneous SMS 201-995 resulted in symptomatic improvement and passage of a formed stool. He also noticed less colicky pain on defaecation. On stopping the SMS 201-995 there was a rebound effect with a recurrence of watery diarrhoea (period F), increased stool output compared to when on SMS 201-995, and general ill-health. In view of the good therapeutic response he was started on 50 pg subcutaneous somatostatin SMS 201-995 twice daily (period G) with good effect and over 9 days learnt the injection technique, at which point we were able to discharge him home. Although there was little change in the stool weight, the stool became formed and he was asymptomatic. He has now been maintained on this regime for 24 months and his symptoms remain controlled. He has had no obvious side effects from SMS 201-995 and he opens his bowels twice a day with no pain. Over this period he has had five admissions with melaena due to bleeding from the tumour as diagnosed endoscopically, but after blood transfusion has returned home each time after 72 hours. A repeat ultrasound shows no increase in tumour size and a gut hormone profile showed that the VIP concentration was lower.
Discussion
Somatostatin was first isolated from the hypothalamus in 1972,3 originally thought to be a specific hypothalamic factor modulating the release of growth hormone, but now known to have a widespread action inhibiting secretion ofgrowth hormone, thyrotrophin, gastrin, gut hormones, insulin and glucagon. 4 
